Intravitreal bevacizumab for treatment of uveitic macular XXXX .

@entity1 @entity4 @entity1596 @entity1103 @entity941
PURPOSE: To evaluate the short-term safety and efficacy of intravitreal bevacizumab for the treatment of @entity1103 ( @entity1103 ) secondary to @entity1596 . DESIGN: Retrospective, noncomparative, interventional case series. @entity1 : Thirteen @entity1 undergoing treatment for recalcitrant uveitic macular @entity4 at one referral center. METHODS: Charts of @entity1 who received one 2.5-mg intravitreal injection of bevacizumab in one eye were reviewed for clinical information including best-corrected Snellen visual acuity (VA), examination findings, optical coherence tomography (OCT) results, and @entity941 angiography results. Kaplan-Meier survival analysis was used to calculate probability success rates. The statistical significance of change in mean retinal thickness and VA was assessed using repeated-measures analysis of variance. MAIN OUTCOME MEASURES: Assessments of changes in best-corrected Snellen VA and OCT retinal thickness were made. RESULTS: Six (46.15%) @entity1 had a decrease in foveal thickness at the end of the follow-up, whereas 5 (38.4%) @entity1 had an improvement of VA by > or =2 lines 84 days or more after the injection. Mean retinal thickness showed a significant decrease over the follow-up (P<0.02). The change in mean logarithm of the minimum angle of resolution VA over the follow-up was not significant (P>0.05). Survival analysis showed that the probability of any improvement in VA increased progressively starting at 6 weeks and reached 81% at 14 weeks. No significant ocular or systemic adverse effects were observed. CONCLUSIONS: These results suggest that a single intravitreal injection of bevacizumab is well tolerated and is associated with short-term improvement in VA and decreased OCT retinal thickness in a considerable proportion of @entity1 with uveitic @entity1103 resistant to conventional therapy. Further evaluation of intravitreal bevacizumab for uveitic @entity1103 in controlled randomized studies is warranted.
